Clinical and pathological features of idiopathic membranous nephropathy with focal segmental sclerosis

CURRENT STATUS: ACCEPTED

jiatong li
Shandong Provincial Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences

Bing Chen
chenbing3668@163.com
Corresponding Author

Caifeng Gao
Jinan Shizhong People's Hospital

Jing Huang
Jinan Shizhong People's Hospital

Yongmei Wang
Jinan Shizhong People's Hospital

Shiyin Zhang
Jinan Shizhong People's Hospital

Ying Xu
Shandong Provincial Hospital Affiliated to Shandong University

Wenkai Guo
Shandong First Medical University & Shandong Academy of Medical Sciences

Rong Wang
Shandong Provincial Hospital Affiliated to Shandong University

DOI: 10.21203/rs.2.12239/v3

SUBJECT AREAS
Urology & Nephrology

KEYWORDS
Idiopathic membranous nephropathy; focal segmental sclerosis; cyclophosphamide; calmodulin inhibitor; prognosis;
Abstract

Background The goal of this study was to investigate the clinical and pathological features and prognosis of idiopathic membranous nephropathy (IMN) with focal segmental lesions. Methods In our hospital, 305 patients with nephrotic syndrome confirmed as IMN by renal biopsy were divided into a non-focal segmental lesion group (FSGS- group) and a focal segmental glomerulosclerosis (FSGS) group (FSGS+ group) and retrospectively analyzed. In all, 180 patients were followed for periods ranging from six months to two years. The general clinicopathological data of both groups were compared, and the effects of different treatment schemes on the prognosis of both groups were observed. Results The FSGS+ group had a longer disease course, higher blood pressure levels, and higher serum creatinine and β2-microglobulin levels than did the FSGS- group (all P < 0.05). Pathologically, the FSGS+ group had increased glomerular sclerosis, glomerular mesangial hyperplasia, and acute and chronic tubular lesion rates (all P< 0.05). The remission rate was lower in the FSGS+ group than in the FSGS- group (64.7% vs 82.2%) and, among patients in the FSGS+ group, was lower in patients treated with calmodulin inhibitors than in those treated with cyclophosphamide (P < 0.01). Survival analysis showed that the FSGS+ group had a poor prognosis (χ²=4.377, P=0.036), and risk factor analysis suggested that age at renal biopsy (P=0.006), 24-hour urinary protein quantity (P=0.01), chronic tubulointerstitial lesions (P=0.055), and FSGS lesions (P= 0.062) were risk factors for worsening renal condition; furthermore, 24-hour urinary protein quantity was an independent risk factor for worsening renal condition. Conclusions Membranous nephropathy with FSGS is a risk factor, but not an independent risk factor, for IMN. Patients with membranous nephropathy with FSGS often present hypertension and tubule injury. The nonselective drug cyclophosphamide is preferred, and calcineurin inhibitors should be used with caution. Key words Idiopathic membranous nephropathy; focal segmental sclerosis; cyclophosphamide; calmodulin inhibitor; prognosis;

Background

Idiopathic membranous nephropathy (IMN) is the leading cause of adult primary nephrotic syndrome. Primary glomerular disease accounted for approximately 20% of IMN and is also the second or a third
The major cause of end-stage renal disease (ESRD) in primary glomerular nephritis patients (1, 2). The pathological manifestations are characterized by the formation of immune complexes in the epithelial cells of the glomerular basement membrane and diffuse thickening of the glomerular basement membrane. The antigens of the glomerular podocytes and/or basement membrane form immune complexes to activate complements, resulting in damage to the filtration barrier, which in turn causes symptoms such as proteinuria (2, 3). The natural course of the disease is long-lasting and variable, with approximately one-third of patients showing varying degrees of persistent proteinuria without disease progression and one-third of patients experiencing progressive deterioration in renal function. ESRD eventually develops in some patients, while other patients show spontaneous remission that can last for many years (4, 5). Therefore, understanding the factors that affect the prognosis is critical for developing treatment plans.

Notably, previous studies have shown that sex, age, blood pressure, estimated glomerular filtration rate (eGFR), serum creatinine proteinuria, and urinary red blood cell count are prognostic factors, while other studies have shown that anti-phospholipase A2 receptor antibody is also an important biochemical indicator to help predict prognosis and guide treatment (5-10). In recent years, nephrological changes, especially membranous nephropathy with focal segmental glomerulosclerosis (FSGS), cannot be ignored as a prognostic index in patients with IMN. However, recent research conclusions are not obvious; Chen Y et al. suggested that segmental sclerosis and tubulointerstitial injury rather than arteriosclerosis or C3 deposition are independent risk factors for ESRD in patients with membranous nephropathy (11). Bazzi C et al. found that patients with IMN with high urinary N-acetyl-beta-glucosaminidase levels and low eGFRs were at an increased risk of progression (12). Uchika Gupta et al. suggested that FSGS may be secondary to membranous nephropathy and may be an indication of poor prognosis (13). However, Saskia F. Heeringa et al. suggested that FSGS is not an accurate predictor of renal outcome in patients with IMN and that renal biopsy results cannot be used to guide decisions on immunosuppressive therapy (14). The different views of these people suggest that the predictive effect of FSGS and other factors on the prognosis of membranous nephropathy is controversial and needs to be further studied.
We also found that approximately one-fifth of patients with membranous nephropathy complicated with FSGS lesions (IMN-FSGS) were found during renal biopsy. In this paper, the clinicopathological features of cases of IMN-FSGS were analyzed. Then, through follow-up, the remission rates of several common clinical regimens were compared, and some suggestions for the treatment of membranous nephropathy complicated with focal segmental sclerosis were proposed. Finally, the risk factors affecting the prognosis of membranous nephropathy were further analyzed.

Methods

1. Patient selection

From January 2015 to December 2017, 305 adult patients at Shandong Provincial Hospital who were diagnosed with nephrotic syndrome confirmed by renal biopsy as IMN and had complete clinical data were included in this study. All the patients had IMN; this condition is universally diagnosed by kidney biopsy through the presence of subepithelial spikes along capillary walls on silver staining, granular IgG and C3 along capillary walls on immunofluorescence, and subepithelial deposits on electron microscopy (EM). However, those with secondary membranous nephropathy caused by systemic lupus erythematosus (SLE), hepatitis B, heavy metal poisoning, other infections or malignancy were excluded. At the time of selection, the patients’ renal function was in the normal range. A total of 180 patients had complete follow-up data for periods ranging from six months to two years. This study was approved by the Ethics Committee of Shandong Provincial Hospital.

2. Clinical and laboratory data

General information: Sex, age, course of disease, and systolic and diastolic blood pressure were taken at the time of biopsy.

Laboratory examination: Kidney damage indicators included peripheral blood leukocyte, hemoglobin, and platelet counts as well as glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST), serum total protein (TP), albumin (ALB), globulin (GLB), blood retinol-binding protein, beta 2-microglobulin, superoxide dismutase (SOD), cystatin C, serum creatinine, urea nitrogen, blood lipid, blood glucose, and blood calcium levels. Routine blood tests evaluated hematuria, proteinuria, and 24-hour urinary protein quantity. Immunological indicators included
serum IgG, IgA, and IgM levels; serum complement (C3 and C4) levels; and the presence of antinuclear antibodies (ANAs) and antineutrophil cytoplasmic antibodies (ANCAs). An ELISA was used to detect the antibody levels of phospholipase A2 receptors (PLA2R) in the serum of patients. Anti-PLA2R ELISA (IgG) kits were purchased from EUROIMMUN Medizinische Labordiagnostika AG. The results were considered negative a t<20 relative units (RU)/mL and positive at ≥20 RU/mL. The eGFR was calculated with a modified Modification of Diet in Renal Disease (MDRD) formula as follows: eGFR [ml/min/1.73 m²]=186×[Scr (μmol/L)/88.4]-1.154×age-0.203(×0.742 if female).

3. Pathological data: Each patient’s renal biopsy included at least 10 glomeruli for histopathological evaluation. Renal puncture tissue was examined by light microscopy, immunofluorescence and electron microscopy. Two renal pathologists, Dr. JZ and Dr. YX, participated in the reading and review of pathological results. Dr. JZ was responsible for the biopsy and preliminary reading of the renal pathology, and Dr. XY was responsible for the re-review of the pathological results. Membranous nephropathy was divided into 4 stages. If two stages were noted at the same time, the relatively higher stage was selected; stages III and IV were defined as advanced pathological stages. Glomeruli were observed for complications involving focal segmental sclerosis, glomerular sclerosis, mesangial proliferative lesions, crescents, endothelial hyperplasia, acute tubular lesions, chronic tubular lesions, inflammatory cell infiltration, small vessel lesions, and so on. FSGS lesions were defined as having focal and segmented distributions of glomerular lesions under light microscopy; they mainly manifested with an increased mesangial matrix and balloon adhesion, accompanied by a small amount of mesangial hyperplasia and corresponding tubular atrophy and renal interstitial fibrosis. The incidence of spherical sclerosis was defined as the existence of spherules in the pathological section. A glomerular mesangial proliferative lesion was defined as the number of cells in the mesangial region greater than or equal to 4. Glomerular endothelial hyperplasia was defined as observable endothelial hyperplasia. Crescent incidence was defined as the presence of cellular or fibrous crescents in one of the glomeruli. The incidence of acute tubulointerstitial lesions was defined as at least 10% renal tubular epithelial flattening, brush edge exfoliation and necrosis, and nontubular inflammatory cell infiltration in the atrophy zone. Chronic renal tubulointerstitial lesions were defined
as more than 10% renal tubular atrophy and interstitial fibrosis. Interstitial inflammatory lesions were characterized by neutrophil infiltration and small vascular lesions due to arterial intimal thickening, elastic layer stratification and hyaline degeneration.

4. Follow-up records

The clinical assessment of the treatments was evaluated by changes in proteinuria and serum creatinine. The nephrotic range for proteinuria was defined as a 24-h urine TP value ≥ 3.5 g. Complete remission (CR) was defined as urine protein < 0.3 g/d in a previously nephrotic patient. Partial remission (PR) was defined as a 50% reduction in the urine protein to a level of proteinuria < 3.5 g/d. We defined worsening renal condition as doubling of the baseline Scr level; we defined end-stage renal disease (ESRD) as a creatinine clearance rate of less than 15 ml/min at last follow-up, start of dialysis or renal transplantation. Serious complications were clinical death or severe pulmonary infection, pulmonary embolism, cerebral infarction, myocardial infarction, tumor and other diseases.

Statistical analyses

SPSS 19.0 statistical software was used for data analysis. Quantitative variables with normal distributions were expressed as x ±s and compared by t-tests, and data with abnormal distributions were expressed as medians and compared by nonparametric test. The categorical variables were expressed as rates and were compared by the χ² test. Patient and renal survival were estimated by the Kaplan-Meier method. The relationships of the covariates to patient and renal survival were evaluated in the univariate analysis with the log-rank test and in the multivariate analysis with the Cox proportional hazards model; the Harrel C statistic was used for verification of the risk factors confirmed by the Cox proportional hazards model. A P value <.05 was considered statistically significant, and a P value <0.01 was considered notably statistically significant. A Cox analysis of risk factors was performed in combination with clinical significance, and P < 0.10 was considered statistically significant.

Results

1. General clinical data
Approximately 252 patients (82.6%) in the IMN without focal segmental sclerosis of the glomeruli group (FSGS- group) and 53 patients (17.4%) in the membranous nephropathy complicated with focal segmental sclerosis of the glomeruli group (FSGS+ group) were included in this study; the general information of the patients is shown in Table 1. The average course of disease in the FSGS+ group was 5.33±5.93 months, which was longer than that in the FSGS- group, and the difference was statistically significant (P < 0.05). Patients in the FSGS+ group were slightly older than those in the FSGS- group, but the difference was not statistically significant (P=0.195). The baseline hypertension rate in the FSGS+ group was 75.5%, which was higher than 46.0% in the FSGS- group (P < 0.01), and the mean systolic and diastolic blood pressures in the FSGS+ group was higher than those in the FSGS- group (P < 0.05). The mean 24-hour urinary protein quantity in the FSGS+ group (6.18 ±3.19) was slightly higher than that in the FSGS- group (5.60 ±3.07), but there was no significant difference (P = 0.227). The levels of serum creatinine (70.28 ±20.25 vs 64.21 ±18.64), β2-microglobulin (2.63 ±1.12 vs 2.15 ±0.66) and retinol-binding protein (56.74 ±17.55 vs 51.11 ±16.52) in the FSGS+ group were higher than those in the FSGS- group. The difference was statistically significant (P < 0.05). In addition, we found that platelet counts and superoxide dismutase (SOD) and serum IgG4 levels in the FSGS+ group were significantly higher than those in the FSGS- group (P < 0.05). The total positive rate of antiphospholipase A2 receptor antibodies in the FSGS- group was similar to that in the FSGS group.

2. Pathological data

In this study, the pathological stages of membranous nephropathy in the FSGS+ group and FSGS-group were mainly stage I and stage II. Immunofluorescence examination of renal biopsy tissue showed that there was no significant difference in the deposition of IgG, IgM, IgA, C3 and C1q between the two groups, but the deposition intensity of fibrous tissue in the FSGS+ group was slightly higher than that in the FSGS- group (P < 0.05). The proportions of glomerular sclerosis, glomerular mesangial hyperplasia and glomerular endothelial hyperplasia in the FSGS+ group were significantly higher than those in the FSGS- group (P < 0.05). The proportions of acute renal tubulointerstitial lesions and chronic renal tubulointerstitial lesions in FSGS +group were also higher than those in the
FSGS- group (P < 0.05). However, the proportion of acute and chronic tubulointerstitial lesions was less than 25%. in all patients. We also observed that the infiltration rate of interstitial inflammatory cells in the FSGS+ group was higher than that in the FSGS- group, but the difference was not statistically significant. The proportion of renal arteriolar lesions in the FSGS+ group was higher than that in the FSGS- group (P < 0.01). The renal pathology of patients is shown in Table 2.

3. Treatments and outcomes

Among the 305 patients, 180 patients were followed for more than 6 months, with an average follow-up time of 12.15±5.27 months. There were 146 patients in the FSGS- group and 34 patients in the FSGS+ group. The patients received specific treatments, including glucocorticoids plus immunosuppressive agents (cyclophosphamide, cyclosporine A, tacrolimus). Our treatment plans were as follows: Patients on drug regimens were treated according to blood pressure and blood lipids. Acetylcholinesterase inhibitors (ACEIs) and angiotensin type 1 receptor blockers (ARBs) were used to control blood pressure below 140/90 mmHg, and statins were used to control blood lipids. Depending on the presence of edema, diuretics were sometimes used. Tacrolimus was administered according to the following regimen: the initial oral dose of tacrolimus was 0.5 mg/(kg·d), and the treatment was continued for at least 6 months. The plasma concentration of tacrolimus was determined for 1 week to maintain the plasma concentration of tacrolimus at 5~10 ng/ml. Cyclosporine A was administered according to the following regimen: the initial oral dose of cyclosporine A was 3-5 mg/(kg·d), and the treatment was continued for at least 6 months. The plasma concentration of cyclosporine A was monitored for 1 week to maintain the plasma concentration of cyclosporine A at 100~200 ng/ml. Cyclophosphamide was administered according to the following regimen: the drug was administered at a static dose of 750 mg/m² body surface area for at least 6 months, and the cumulative dose was 6-8 g. All patients were given a sufficient dose of prednisone 1mg/(kg·d). After 8 weeks of adequate treatment, the dose size was reduced by 5 mg every 2 weeks and then held constant at a low dose of 10 mg/d. The total course of treatment was at least 9 months. The overall response rate (including the CR and PR) in the FSGS+ group was 64.7%, which was significantly lower than that in the FSGS-group (82.2%), and the difference was statistically significant (P=0.024). The CR rate and PR rate
were 23.5% and 41.2% in the FSGS+ group and 36.3% and 45.9% in the FSGS- group, respectively. Further subgroup analysis showed that there was no significant difference in the remission rate between the two groups treated with sufficient corticosteroids and cyclophosphamide at the same time. The overall remission rate in the FSGS+ group was significantly lower than that in the FSGS-group (50.0% vs 86.2%, P < 0.01). See Table 3 for details. We performed subgroup analysis of the PLA2R- group and the PLA2R+ group. The remission rate (including CR and PR) in the PLA2R+ group was 75.4%, which was significantly lower than that in the PLA2R- group (89.7%). In the PLA2R+ group, the remission rate decreased as the PLA2R titer increased, especially in the high-titer group; the overall remission rate was 56.7%. The total remission rate in the high-titer group was significantly lower than that in the PLA2R+ group. However, in the PLA2R- group and the PLA2R+ group, there was no significant difference in the remission rate between the FSGS+ group and the FSGS- group, between the PLA2R+ group and the FSGS- group, or between the FSGS+ group and the FSGS- group. In short, the remission rate was not related to FSGS+ but was significantly related to the titer of PLA2R. For more information, see Table 4. Consistent with the above results, our results showed that the total 24-hour proteinuria level in the FSGS+ group was significantly higher than that in the FSGS-group after treatment, and the difference was statistically significant (P < 0.05). The serum creatinine level in the FSGS+ group was significantly higher than that in the FSGS- group after treatment (P < 0.05). The subgroup analysis showed that the total 24-hour proteinuria levels in the FSGS group were significantly higher than those in the FSGS- group after treatment (P < 0.05), mainly in patients with half-dose corticosteroids plus cyclosporine or tacrolimus (P < 0.05). The serum creatinine level in the FSGS group was significantly higher than that in the FSGS- group after tacrolimus treatment (P < 0.05). See Table 4 for details.

4. Prognosis analysis

At the end of the follow-up, 5 cases of worsening renal condition were identified, including 2 cases in the FSGS+ group and 3 cases in the FSGS- group. Four cases occurred in the corticosteroids plus cyclosporine or tacrolimus treatment group. The main reason for this result may be the high concentration of cyclosporine or tacrolimus; 2 patients presented negative proteinuria and 2 cases did
not experience remission. Another case occurred in the corticosteroids plus cyclophosphamide group with the PR of proteinuria; the specific reasons were unknown. During follow-up, severe complications were observed in 3 patients; severe pneumonia occurred in 2 patients (1 death but no worsening renal condition) and intracranial fungal infection occurred in 1 patient. See Table 5 for details. Using a Kaplan-Meier survival plot, the log-rank test found that the 2 groups had significant renal survival differences ($\chi^2 = 4.377, P = 0.036$). The 2-year renal survival rate was 88.0% in the FSGS+ group and 98.5% in the FSGS group, as shown in Fig. 1. The Cox univariate analysis showed that the variables associated with worsening renal condition included age at the time of renal biopsy, 24-hour urinary protein quantification, chronic tubulointerstitial lesions and FSGS lesions, as shown in Table 6. A Cox proportional hazard model was used to analyze age; 24-hour urine protein, β2-microglobulin, and cystatin levels; chronic tubulointerstitial lesions and FSGS lesions at the time of renal biopsy. Twenty-four-hour urinary protein was found to be an independent risk factor for worsening renal condition, as shown in Table 7.

Discussion
In recent years, a number of studies have reported the effect of lesions on the clinical characteristics and renal prognosis of IMN patients with FSGS, but the conclusions varied. Some studies have shown that the incidence of FSGS in IMN patients is between 12.8% and 43% (7, 8, 13), which is to our incidence of 17%. Dumoulin A et al. found that patients with FSGS had an increased degree of hypertension and an increased rate of severe renal damage (7). Qiu-hua Gu et al. suggested that hypertension, abnormal serum creatinine levels, microscopic hematuria incidence and 24-hour urinary protein excretion were higher in the FSGS+ group than those in the FSGS- group (15). Some of these results were the same as ours, and some were different. Our analysis shows that the main reason was the degree of severity of the patients involved in the group. The renal functions of the patients we enrolled were in the normal range, and the pathological injuries were relatively minor, so the hematuria and renal injuries were relatively minor.

In terms of pathology, we observed that the proportions of FSGS glomerulosclerosis, glomerular mesangial hyperplasia, glomerular endothelial hyperplasia and renal arteriolar mucoid degeneration
in the FSGS+ group were significantly higher than those in the FSGS- group, and the proportions of acute tubular lesions and chronic tubular lesions were also higher than those in the FSGS- group. The Gupta R study showed that patients with FSGS had more severe renal lesions, a higher mean staging of membranous lesions, more nonfunctional glomeruli, more severe mesangial hyperplasia, and more severe interstitial fibrosis and vascular changes than those without FSGS(13). Qiu-hua Gu et al. showed that renal tubular atrophy, interstitial infiltration and were relatively common and severe (15). The above studies were basically consistent with our observations, but we relaxed the standard for chronic tubular injury to 10% (the proportion of chronic tubular injury in all patients was not more than 25%). This change was made because we found that 10% of renal tubular injuries indicate a poor prognosis, so we reduced the percentage. For treatments and outcomes, the patients we selected were not given nonspecific treatment and observed for 6 months but rather were given specific treatment directly because the average daily urinary protein of the patients was more than 6 g. These patients had at least a moderate or high risk of progressive disease. In addition, CR had a better long-term prognosis, and PR reduced the risk of renal failure (16, 17). A recent study showed that after IMN patients achieved CR or PR, the risk of renal function deterioration was significantly reduced (18). For IMN patients with severe proteinuria, early treatment may be an effective method. We found that the overall response rate of the FSGS+ group was 64.7%, which was significantly lower than that of the FSGS- group (82.2%). Further subgroup analysis showed that there was no difference between the two groups when using the corticosteroids plus cyclophosphamide regimen, but the remission rate associated with cyclosporine and tacrolimus in the FSGS+ group was lower than that in the control group. According to our analysis, patients with membranous nephropathy complicated with FSGS had high levels of proteinuria, most patients had chronic tubular interstitial lesions, and the kidneys themselves has ischemic manifestations. Cyclosporine and tacrolimus are calmodulin neurophosphatase inhibitors (CNIs), and their mechanism is similar. One stabilizes the cytoskeleton of podocytes by inhibiting the expression of transient receptor potential cation channel 6 (TRPC6) proteins and calmodulin neurophosphatase (CaN), thereby reducing urinary protein (19, 20). The other inhibits the translocation of nuclear factors in activated T cells (NFAT) by binding to calmodulin
neurophosphatase, thus blocking the transcription of early T lymphocyte activation genes induced by T cell receptor (TCR)-CD3, and blocking the transition of T cells from the G0 phase to the G1 phase (21). It has been reported that excessive doses of cyclosporine can lead to increased renal vascular resistance, especially glomerular afferent arterioles, resulting in renal ischemia. This might be the mechanism responsible for chronic tubular interstitial and vascular changes associated with chronic calcineurin toxicity (22). However, nephrotoxicity associated with CNIS is an important issue of concern, limiting its clinical application. In this study, we observed a significant increase in serum creatinine during CNIS therapy. We speculated that the patients with membranous nephropathy with focal segmental sclerosis had chronic tubular interstitial injury. In these patients, the long-term use of cyclosporine and tacrolimus may further reduce the original glomerular blood supply and further aggravate chronic injury of the tubulointerstitial tissue, especially in patients with high blood concentrations, so the remission rate is lower than that of the cyclophosphamide group. Therefore, cyclosporine and tacrolimus should be used with caution in such patients, and their side effects should be closely observed.

The survival curve showed that the renal survival rate of the FSGS+ group was lower than that of the FSGS- group. Risk factor analysis revealed that age at renal biopsy; 24-hour urinary protein, $\beta_2$-microglobulin, and cystatin levels; chronic tubulointerstitial disease; and complication with FSGS were all risk factors for IMN. According to the Cox proportional hazard model, only 24-hour urinary protein was an independent risk factor for worsening renal condition. The univariate Cox analysis by Ke Zuo et al. showed that as eGFR decreased, proteinuria, hypertension, the $N$-acetyl-$\beta$-D-glucosidase (u-NAG) level and the retinol-binding protein (u-RBP) level increased in the nephrotic system. Tubular interstitial disease and renal arteriopathy are risk factors for renal survival, but total/segmental sclerosis is not a risk factor. The Cox multivariate analysis showed that decreased eGFR and chronic tubulointerstitial damage were independent risk factors for end-stage renal disease (ESRD)(10). Shiiki H et al. suggested that tubulointerstitial lesions are an important predictor of the progression of nephrotic syndrome to end-stage nephropathy (10). Dumoulin A and Gupta, R. et al. considered chronic tubulointerstitial damage as an independent risk factor for ESRD and that the presence of
focal segmental glomerulosclerosis was the most important prognostic factor (7, 13). This was similar to the results of our study. Although membranous nephropathy with segmental sclerosis was a univariate predictor of ESRD, it was not an independent risk factor in the multivariate analysis. The limitations of this study were that it was a retrospective observational study, and some patients were lost during the follow-up, leading to a bias in the results analysis. We consider that membranous nephropathy complicated with FSGS is still an important prognostic factor in combination with the above pathological and clinical comparisons.

To date, the potential mechanism of FSGS lesions in IMN remains unclear. Most studies suggest that primary and secondary focal segmental glomerulosclerosis is thought to be caused by intrarenal vasodilation, increased glomerular capillary pressure, and structural and functional adaptation mediated by plasma flow velocity. The podocytes of the glomeruli are active cells with mechanical sensors that respond to positional stimulation and shear stress. Due to compensatory effects, the residual glomerular volume and surface area increase, exerting mechanical stress on the podocytes and causing podocyte damage, which is probably the mechanism of membranous nephropathy with focal segmental sclerosis. (23). Michio Nagata recently found that segmental glomerulosclerosis in FSGS seems to be based on the focal glomerular response to halt protein leakage from the GBM after podocyte loss, functioning as a wound healing process (24). However, Alain Meyrier observed that some cases of secondary FSGS improved after the use of immunosuppressive agents, which may be lateral confirmation that this disease is related to immune factors (25). In our study, our two pathologists were unable to distinguish the pathological changes of endothelial hyperplasia and foot process fusion at the FSGS site under a light microscope, while electron microscopy could not render the sclerotic globules. Therefore, it was impossible to further determine whether these sclerotic globules were secondary factors or primary factors. However, upon analysis of the relevant literature and the patients’ medical history, we discovered that most of these patients had focal segmental lesions caused by various secondary factors such as hypertension.

Of course, there are still some limitations in our research. First, this was a single-center retrospective clinical study. Second, the observation time was short, and there was a certain degree of loss to
follow-up, which may cause deviation of the final data. Therefore, further large-scale clinical and basic research is needed to further confirm these results.

Conclusion
The occurrence of segmental glomerulosclerosis can occur in the course of membranous nephropathy. Pathological changes, such a manifestation of chronic kidney injury, often indicate a poor prognosis of membranous nephropathy. Membranous nephropathy complicated with FSGS is a risk factor for IMN, but it is not an independent risk factor. Patients with membranous nephropathy complicated with FSGS often present hypertension and tubule injury; therefore, when selecting immunosuppressants, nonselective cyclophosphamide should be the first choice, and CNIs should be used cautiously.

Abbreviations
IMN: idiopathic membranous nephropathy; FSGS: focal segmental glomerulosclerosis; ESRD: end-stage renal disease; SLE, systemic lupus erythematosus; IMN-FSGS: membranous nephropathy complicated with FSGS lesions; SLE, systemic lupus erythematosus; ALT: glutamic pyruvic transaminase; AST: glutamic oxaloacetic transaminase; TP: serum total protein; ALB: albumin; GLB: globulin; SOD: superoxide dismutase; ANA: antinuclear antibody; ANCA: antinuclear cytoplasmic antibody; PLA2R: phospholipase A2 receptors; CR: Complete remission; PR: Partial remission; CNIs: calmodulin neurophosphatase inhibitors; TRPC6: transient receptor potential cation channel 6; CaN: calmodulin neurophosphatase; NFAT: nuclear factors in activated T cells; u-NAG: N-acetyl-β-D-glucosidase; u-RBP, retinol-binding protein.

Declarations

Ethics approval and consent to participate
The data collection of related cases has been approved by the Ethics Committee of the Affiliated Provincial Hospital of Shandong University (LCYJ: No. 2019-105). Oral and written informed consent to participation is obtained from all study participants by study personnel prior to any study related procedure. All participants receive both written and oral information about the study before giving consent.

Consent for publication
Not applicable.

**Availability of data and materials**

The datasets used and/or analyzed during the current study will be available from the corresponding author on reasonable request.

**Competing interest**

There are no conflicts of interest.

**Finding**

This study was supported by grants from the Primary Research & Development Plan of Shandong Province (2018GSF118227) and Science and Technology Plan (673 and 741) of Shizhong District of Jinan City. The funding bodies provide staff costs for collecting patient information but had no influence on the design of the study, the collection, analysis and interpretation of data or in writing the manuscript.

**Authors’ contributions**

JL is the coordinating investigator, CG, JH, YW, SJ, YX and WG are investigators/subinvestigators in the respective study centers, and BC and RW are the sponsors of the study. JZ and YX participated in the reading and review of pathological results. JL drafted the manuscript, and all co-authors reviewed and revised the article. All authors read and approved the final manuscript.

**Acknowledgments**

Thanks for Ruihua Song and Shimin Zhao to help collecting data.

**Author details**

1. Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong 250021, P.R. China

2. Department of Nephrology, Shandong Provincial Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences Shandong, P.R. China

3. Department of Nephrology, Jinan Shizhong People’s Hospital, Shandong 250002, P.R. China
Corresponding author: Bing Chen, Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong 250021, P.R. China. Tel./fax: +86 531 6877 6294. E-mail address: chenbing3668@163.com.

References

1. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. The Lancet. 2015;385(9981):1983-92.

2. Ronco P, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015;68(1):57-62.

3. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-97.

4. Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. Biomed Res Int. 2015;2015:249740.

5. Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 2010;21(4):697-704.

6. SHIIKI H, SAIITO T, NISHITANI Y, MITARAI T, YORIOKA N, YOSHIMURA A, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney International. 2004;65:1400-7.

7. Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41(1):38-48.

8. S W. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney international. 1992;41:428-34.

9. van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, et al.
Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93(4):1016-7.

10. Zuo K, Wu Y, Li SJ, Xu F, Zeng CH, Liu ZH. Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol. 2013;79(6):445-53.

11. Chen Y, Tang L, Feng Z, Cao X, Sun X, Liu M, et al. Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function. Italian Society of Nephrology. 2014;27(3):307-16.

12. Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary N-acetyl-beta-glucosaminidase and estimated Glomerular filtration rate may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. Nephrology (Carlton). 2018;23(2):175-82.

13. Gupta R, Sharma A, Mahanta PJ, Jacob TG, Agarwal SK, Roy TS, et al. Focal segmental glomerulosclerosis in idiopathic membranous glomerulonephritis: a clinicopathological and stereological study. Nephrol Dial Transplant. 2010;25(2):444-9.

14. Heeringa SF, Branten AJ, Deegens JK, Steenbergen E, Wetzels JF. Focal segmental glomerulosclerosis is not a sufficient predictor of renal outcome in patients with membranous nephropathy. Nephrol Dial Transplant. 2007;22(8):2201-7.

15. Gu QH, Cui Z, Huang J, Zhang YM, Qu Z, Wang F, et al. Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study. Medicine (Baltimore). 2016;95(21):e3786.

16. Troyanov Se, A.Wall C, A.Miller J, W.Scholey J, C.Cattran D. Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney International. 2014;66:1199-205.
17. Laluck BJ, Cattran Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. American Journal of Kidney Diseases. 1999;33(6):1026-32.

18. Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924-30.

19. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719-32.

20. Winn 2007 Young Investigator Award: TRP'ing into a new era for glomerular disease. J Am Soc Nephrol. 2008;19(6):1071-5.

21. Li ZQ, Hu ML, Zhang C, Wang YM. Efficacy and safety of tacrolimus vs. cyclophosphamide for idiopathic membranous nephropathy: A meta-analysis of Chinese adults. J Huazhong Univ Sci Technolog Med Sci. 2015;35(5):623-8.

22. Feutren C, Mihatsch M. Risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. The New England Journal of Medicine. 1992 Jun 18;329(25):1654-60.

23. Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21(11):1835-41.

24. Nagata M, Kobayashi N, Hara S. Focal segmental glomerulosclerosis; why does it occur segmentally? Pflugers Arch. 2017;469(7-8):983-8.

25. Meyrier A. Treatment of focal segmental glomerulosclerosis. Expert opinion on pharmacotherapy. 2005;6(9):1539-49.

Tables
Table 1. Clinical and Laboratory Findings at Time of Renal Biopsy

Note: SBP, systolic blood pressure; DBP, diastolic blood pressure; UP, 24-h urinary protein; TP, serum total protein; ALB, serum albumin; BUN, blood urea nitrogen; Cr, serum creatinine concentration; SOD, superoxide dismutase; CysC, cystatin C; ALT, glutamic pyruvic transaminase; AST, glutamic oxaloacetic transaminase; GLB, globulin; C3 and C4, complement 3 and 4; ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; PLA2R, phospholipase A2 receptors. Compared with the FSGS- group and the FSGS+ group, $P<0.05$, $P<0.01$. 
|                    | IMNN=N=305 | FSGS-N=252 | FSGS+N=53 | P value |
|--------------------|------------|------------|----------|---------|
| Age (year)         | 44.23±13.95| 43.62±13.61| 46.53±15.09| 0.195   |
| Sex (female(%))    | 114/305(37.4)| 96/252(38.1)| 18/53(33.9) | 0.572   |
| Duration of illness (month) | 3.87±4.68 | 3.46±4.20 | 5.33±5.93 | 0.028   |
| SBP (mmHg)         | 141.57±19.98| 138.03±19.28| 152.50±18.46| 0.003   |
| DBP (mmHg)         | 87.52±13.24| 85.68±12.46| 93.23±14.23 | 0.019   |
| Urine RBC/HPF      | 13.92±16.72| 13.59±15.98| 15.18±19.45| 0.557   |
| UP (g/L)           | 5.71±3.09 | 5.60±3.07 | 6.18±3.19 | 0.227   |
| WBC (×10^9/L)      | 7.64±3.27 | 7.61±3.14 | 7.73±3.77 | 0.831   |
| HGB (g/L)          | 136.12±17.36| 136.40±17.31| 134.82±17.74| 0.604   |
| PLT (×10^9/L)      | 260.06±61.47| 254.64±58.81| 280.85±67.45| 0.008   |
| AST (u/L)          | 23.06±14.14| 21.98±10.32| 27.16±23.24| 0.138   |
| ALT (u/L)          | 25.55±22.18| 24.46±17.49| 29.70±34.53| 0.145   |
| SOD (u/mL)         | 96.36±29.21| 92.33±26.43| 110.57±34.19| 0.005   |
| TP (g/L)           | 45.58±7.20 | 45.37±6.78 | 46.34±6.67 | 0.408   |
| ALB (g/L)          | 23.82±5.26 | 23.77±5.09 | 24.05±6.05 | 0.723   |
| GLU (mmol/L)       | 11.22±1.41 | 5.24±1.47 | 5.12±1.05 | 0.628   |
| BUN (mmol/L)       | 5.45±1.91 | 5.44±1.86 | 5.49±2.11 | 0.873   |
| CREA (µmol/L)      | 66.26±19.03| 64.21±18.64| 70.28±20.25| 0.036   |
| CysC (mg/L)        | 1.05±0.29 | 1.05±0.28 | 1.06±0.33 | 0.745   |
| BMG (mg/L)         | 2.25±0.80 | 2.15±0.66 | 2.63±1.12 | 0.010   |
| RBP (mg/L)         | 52.32±16.87| 51.11±16.52| 56.74±17.55| 0.047   |
| Ca (mmol/L)        | 2.16±0.26 | 2.15±0.27 | 2.18±0.21 | 0.468   |
| CHOL (mmol/L)      | 8.85±2.72 | 8.91±2.76 | 8.63±2.59 | 0.551   |
| HDL-C (mmol/L)     | 1.74±0.59 | 1.75±0.58 | 1.74±0.62 | 0.930   |
| LDL-C (mmol/L)     | 5.33±2.18 | 5.38±2.19 | 5.14±2.11 | 0.531   |
| PLA2R (POSITIVE %) | 132/175(75.4)| 98/132(74.2)| 34/43(79.0) | 0.523   |
| IgG4 (mg/L)        | 313.08±248.47| 283.81±223.11| 380.84±291.16| 0.044   |
| IgG (g/L)          | 5.28±2.53 | 5.23±2.47 | 5.50±2.81 | 0.547   |
| IgM (g/L)          | 1.09±0.54 | 1.11±0.56 | 0.99±0.42 | 0.191   |
| IgA (g/L)          | 2.20±0.87 | 2.19±0.79 | 2.22±1.14 | 0.912   |
| C3 (g/L)           | 1.16±0.25 | 1.16±0.25 | 1.17±0.25 | 0.804   |
| C4 (g/L)           | 0.29±0.08 | 0.28±0.08 | 0.29±0.07 | 0.528   |
| C1q (mg/L)         | 207.13±41.49| 206.48±40.21| 210.11±47.18| 0.612   |

Table 2. Histopathologic Parameters at the Time of Renal Biopsy

Compared with the FSGS- group and the FSGS+ group, P<0.05, P<0.01.
| Pathological stage(%) | FSGS-(N=252) | FSGS+(N=53) | P value |
|----------------------|--------------|-------------|---------|
| I                    | 136/252(53.9) | 23/53(43.4) | 0.161  |
| II                   |              |             |         |
| III+IV               | 114/252(45.3) | 30/53(56.6) | 0.132  |
|                      | 2/252(0.8)   | 0           |         |

| Tissue IgG | 2.77±0.63 | 2.63±0.82 | 0.370  |
| Tissue IgM  | 0.45±0.81 | 0.43±0.75 | 0.967  |
| Tissue IgA  | 2.30±0.81 | 2.13±1.36 | 0.597  |
| Tissue C₃   | 1.47±1.08 | 1.31±1.00 | 0.364  |
| Tissue Fib  | 0.53±1.22 | 0.13±0.48 | 0.025  |
| Tissue C₁q  | 0.80±1.17 | 0.53±0.77 | 0.146  |

| Pathological characteristics | FSGS-(N=252) | FSGS+(N=53) | P value |
|------------------------------|--------------|-------------|---------|
| Global sclerosis             | 105/252(40.5) | 30/53(56.6) | 0.047  |
| Glomerular mesangial hyperplasia | 67/252(26.6) | 30/53(56.6) | 0.000  |
| Crescents                    | 2/252(0.8)   | 1/53(1.8)   | 0.464  |
| Hyperplasia endothelialitis  | 5/252(1.9)   | 6/53(11.3)  | 0.001  |
| Acute renal tubular lesions  | 12/252(4.7)  | 7/53(13.2)  | 0.021  |
| Chronic renal tubular lesions | 15/252(5.9)  | 17/53(32.0) | 0.000  |
| Inflammatory cell infiltration | 8/252(3.2)   | 4/53(7.5)   | 0.137  |
| Vascular disease             | 57/252(22.6) | 23/53(43.4) | 0.002  |

**Table 3** Remission rate after 1 year of follow-up treatment

Note: CR, Complete remission; PR, Partial remission; CsA, cyclosporin; Pred, predisone; TAC, tacrolimus; CTX, cyclophosphamide; MN, membranous nephropathy; FSGS-, membranous nephropathy without focal segmental glomerulosclerosis; FSGS+, membranous nephropathy with focal segmental glomerulosclerosis.

Compared with the FSGS- group and the FSGS+ group, P<0.05, P<0.01.
| Group                      | Complete Remission Rate (CR) | Partial Remission Rate (PR) | CR+PR          |
|---------------------------|------------------------------|-----------------------------|----------------|
| PLA2R-                    | 13/29 (44.8%)                | 13/29 (44.8%)               | 26/29 (89.7%)  |
| FSGS- (N=27)              | 12/27 (44.4%)                | 12/27 (44.4%)               | 24/27 (88.9%)  |
| FSGS+ (N=2)               | 1/2 (50.0%)                  | 1/2 (50.0%)                 | 2/2 (100%)     |
| PLA2R+                    | 33/11827.9%                  | 56/11847.5%                 | 89/11875.4%    |
| FSGS- (N=100)             | 28/10028.0%                  | 47/10047.0%                 | 75/10273.5%    |
| FSGS+ (N=18)              | 5/1827.8%                    | 9/1850.0%                   | 14/1877.8%     |
| Low titer PLA2R+14-86     | 19/47 (40.4%)                | 20/47 (42.6%)               | 39/47 (82.9%)  |
| FSGS - (N=9)              | 3/9 (33.3%)                  | 4/9 (44.4%)                 | 7/9 (77.8%)    |
| Low titer PLA2R+87-204    | 4/21 (19.05%)                | 14/21 (66.7%)               | 18/21 (85.7%)  |
| FSGS+ (N=4)               | 1/4 (25.0%)                  | 2/4 (50.0%)                 | 3/4 (75.0%)    |
| High titer PLA2R+>204     | 6/32(18.7%)                  | 12/32(37.5%)                | 18/32(56.3%)   |
| FSGS - (N=5)              | 1/5 (20.0%)                  | 2/5 (40.0%)                 | 3/5 (60.0%)    |

**Table 4:** Remission rate after 1 year of follow-up treatment between PLA2R+ and PLA2R- group

**Note:** FSGS-, membranous nephropathy without focal segmental glomerulosclerosis; FSGS+, membranous nephropathy with focal segmental glomerulosclerosis.

| Group                      | CR  | PR  | CR+PR         |
|---------------------------|-----|-----|---------------|
| Total (N=180)             | CMN | FSGS-(N=146) | FSGS+(N=34) |
| Complete remission rate (CR) | 13/29 | 12/29 | 1/29 | 26/29 |
| Partial remission rate (PR) | 20/47 | 4/21 | 1/4 | 28/57 |
| CR+PR                      | 39/47 | 25/47 | 1/29 | 65/76 |

**Table 5. Data after 1 year of follow-up treatment**

**Note:** ALB, serum albumin; BUN, blood urea nitrogen; CREA, serum creatinine concentration; eGFR
estimated Glomerular filtration rate

Compared with the FSGS- group and the FSGS+ group, P<0.05, P<0.01.

| Total     | 24-HUPRO(g/L) | ALB(g/L) | CREA(µmol/L) | BUN(mmol/L) | New DM(%) |
|-----------|---------------|----------|--------------|-------------|-----------|
| FSGS-(N=146) | 1.27±1.58     | 36.82±5.75 | 63.89±17.05  | 1.49±2.20   | 22/146(15.1) |
| FSGS(N=34)   | 2.18±2.34     | 34.74±8.86 | 76.99±35.05  | 2.74±2.71   | 4/34(11.8)   |
| Pred+Ctx FSGS-(N=81) | 1.37±1.83     | 36.22±5.94 | 59.36±13.46  | 5.30±1.59   | 11/81(13.6)  |
| FSGS+(N=18)  | 1.44±1.95     | 35.16±8.77 | 72.55±43.73  | 7.33±2.88   | 2/18(11.1)   |
| Ped+Csa FSGS-(N=34) | 1.11±1.24     | 37.68±5.90 | 72.50±21.68  | 6.17±1.60   | 5/34(14.7)   |
| FSGS+(N=9)   | 2.89±2.81     | 34.28±7.59 | 77.74±12.67  | 7.25±3.14   | 2/9(11.1)    |
| Ped+F506 FSGS-(N=31) | 1.15±1.11     | 37.46±4.93 | 67.08±16.16  | 6.21±1.80   | 6/31(19.4)   |
| FSGS+(N=7)   | 2.71±2.49     | 35.07±11.80| 87.00±31.15  | 6.49±1.69   | 0          |

Table 6. Prognosis of patients in the two groups

FSGS-, membranous nephropathy without focal segmental glomerulosclerosis; FSGS+, membranous nephropathy with focal segmental glomerulosclerosis.

| Prognosis             | FSGS-(N=146) | FSGS(N=34) |
|-----------------------|--------------|------------|
| Renal worsening condition | 2            | 3          |
| Clinical death        | 0            | 1          |
| Severe infection      | 2            | 1          |
| Complete remission   | 53           | 10         |
| Partial remission    | 67           | 12         |

Table 7. Univariate Cox regression analysis of worsening renal condition risk in patients with IMN

Note: CG, chronic glomerulopathy; VL, vascular lesion; Cys C, cystatin c; β2-MG, β2-microglobulin;

DF: degree of freedom; Sig: significance

|         | B     | SE    | Wald  | DF | Sig | Exp(B) |
|---------|-------|-------|-------|----|-----|--------|
| Age     | .158  | .058  | 7.520 | 1  | .006 | 1.172  |
| 24-HUPRO| .262  | .102  | 6.611 | 1  | .010 | 1.300  |
| Cys C   | 2.514 | .931  | 7.295 | 1  | .007 | 12.356 |
| β2-MG   | .839  | .290  | 8.379 | 1  | .004 | 2.314  |
| FSGS    | -1.714| .919  | 3.477 | 1  | .062 | .180   |
| GC      | -1.609| .914  | 3.101 | 1  | .078 | .200   |
| VL      | 2.150 | 1.122 | 3.671 | 1  | .055 | 8.581  |

Table 8. Multivariate Cox regression analysis of worsening renal condition risk in patients with IMN

Note: CG, chronic glomerulopathy; VL, vascular lesion; Cys C, cystatin c; β2-MG, β2-microglobulin;

DF: degree of freedom; Sig: significance
|          | B    | SE   | Wald  | DF | Sig | Exp(B) |
|----------|------|------|-------|----|-----|--------|
| Age      | .100 | .070 | 2.045 | 1  | .153| 1.105  |
| 24-HUPRO | .302 | .145 | 4.309 | 1  | .038| 1.352  |
| Cys C    | 1.777| 1.843| .929  | 1  | .335| 5.911  |
| β₂-MG    | .330 | .586 | .318  | 1  | .573| 1.391  |
| FSGS     | -.955| 1.302| .539  | 1  | .463| 1.385  |
| CG       | .909 | 1.344| .457  | 1  | .499| 2.481  |
| VL       | -1.043| 1.563| .446  | 1  | .504| .352   |

**Figures**

**Figure 1**

FSGS can predict renal outcome in patients with iMN. Note: See methods for definition of worsening renal condition. Renal survival is depicted for patients with FSGS (FSGS-, red line; n=146) and without FSGS (FSGS+, blue line; n=34).